Lexaria Bioscience Corp. financial data

Symbol
LEXX, LEXXW on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 740 Mccurdy Road, Kelowna, British Columbia, Canada
State of incorporation
NV
Fiscal year end
August 31
Former names
Lexaria Corp. (to 5/11/2016), LEXARIA CORP. (to 5/11/2016)
Latest financial report
10-Q - Q2 2024 - Jul 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.07K % +162%
Quick Ratio 0.96 % -94.4%
Debt-to-equity 4.84 % -40.1%
Return On Equity -88.4 % +28.7%
Return On Assets -84.1 % +26.4%
Operating Margin -1.13K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.8M shares +95.4%
Common Stock, Shares, Outstanding 15.8M shares +95.4%
Entity Public Float 21M USD -22.2%
Common Stock, Value, Issued 15.8K USD +95.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 411K USD +34.1%
Revenue from Contract with Customer, Excluding Assessed Tax 151K USD +54.8%
Research and Development Expense 1.89M USD -46.2%
General and Administrative Expense 3.18M USD +10.3%
Operating Income (Loss) -4.66M USD +27.4%
Net Income (Loss) Attributable to Parent -4.85M USD +29.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.27M USD -60.9%
Marketable Securities, Current 46.3K USD -82.8%
Accounts Receivable, after Allowance for Credit Loss, Current 208K USD +21%
Inventory, Net 0 USD -100%
Assets, Current 9.09M USD +115%
Property, Plant and Equipment, Net 219K USD -20.8%
Operating Lease, Right-of-Use Asset 143K USD
Assets 10M USD +91.2%
Liabilities, Current 156K USD -85.2%
Operating Lease, Liability, Noncurrent 18.3K USD -69.5%
Liabilities 271K USD -77.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -21.9K USD
Retained Earnings (Accumulated Deficit) -49.4M USD -10.9%
Stockholders' Equity Attributable to Parent 10.1M USD +130%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.75M USD +141%
Liabilities and Equity 10M USD +91.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.18M USD +5.11%
Net Cash Provided by (Used in) Financing Activities 1.82M USD
Net Cash Provided by (Used in) Investing Activities -40K USD -14.9%
Common Stock, Shares Authorized 220M shares 0%
Common Stock, Shares, Issued 15.8M shares +95.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 602K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.46M USD +167%
Deferred Tax Assets, Gross 9.58M USD +21.8%
Operating Lease, Liability 143K USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.78M USD +24.8%
Lessee, Operating Lease, Liability, to be Paid 167K USD
Operating Lease, Liability, Current 41.8K USD +8.68%
Lessee, Operating Lease, Liability, to be Paid, Year Two 37.1K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 8.96K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 37.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 38.6K USD
Operating Lease, Payments 8.96K USD -80%
Additional Paid in Capital 59.5M USD +21.7%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 170K USD